Remarks

By the foregoing amendments, the specification has been amended to update the priority information upon entry of the present application into the U.S. National Phase; to insert the Abstract (containing the same text of the Abstract as filed in the International application that appears on the face page of the published International application) into the proper location for U.S. practice; and to replace the sequence listing as filed in the international application with a substitute sequence listing in proper format for U.S. practice; these amendments add no new matter. In accordance with 37 C.F.R. §§ 1.821-1.825, the computer readable and paper copies of the substitute sequence listing submitted herewith are the same and include no new matter.

By the foregoing amendments, claims 9, 14, 22, 23 and 25-51 are cancelled without prejudice to or disclaimer of the subject matter therein. Claims 3-6, 8, 12, 13, 15-21 and 24 are sought to be amended. These amendments are sought to place the claims into better form for U.S. practice, do not introduce new matter, and are supported in the specification, for example, at original claims 9, 14, 22 and 23. Hence, their entry and consideration are respectfully requested. Upon entry of the foregoing amendments, claims 1-8, 10-13, 15-21 and 24 are pending in the application, with 1 being the sole independent claim.

BEERLI et al. Appl. No. To be Assigned (U.S. Nat'l Phase of PCT/EP2004/005762)

Conclusion

Prompt entry and favorable consideration of the foregoing amendments are respectfully requested. Applicants believe the present application is in condition for immediate examination. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Brian J. Del Buono Attorney for Applicants

Registration No. 42,473

Date: November 28, 2005

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600